<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Human minor histocompatibility antigens (mHags) play an important role in the induction of cytotoxic T lymphocyte (CTL) reactivity against <z:hpo ids='HP_0001909'>leukemia</z:hpo> after human histocompatibility leukocyte antigen (HLA)-identical allogeneic bone marrow transplantation (BMT) </plain></SENT>
<SENT sid="1" pm="."><plain>As most mHags are not <z:hpo ids='HP_0001909'>leukemia</z:hpo> specific but are also expressed by <z:mpath ids='MPATH_458'>normal</z:mpath> tissues, antileukemia reactivity is often associated with life-threatening <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we describe a novel mHag, HB-1, that elicits donor-derived CTL reactivity in a B cell <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>) patient treated by HLA-matched BMT </plain></SENT>
<SENT sid="3" pm="."><plain>We identified the gene encoding the antigenic <z:chebi fb="7" ids="16670">peptide</z:chebi> recognized by HB-1-specific CTLs </plain></SENT>
<SENT sid="4" pm="."><plain>Interestingly, expression of the HB-1 gene was only observed in <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> cells and Epstein-Barr virus-transformed B cells </plain></SENT>
<SENT sid="5" pm="."><plain>The HB-1 gene-encoded <z:chebi fb="7" ids="16670">peptide</z:chebi> EEKRGSLHVW is recognized by the CTL in association with HLA-B44 </plain></SENT>
<SENT sid="6" pm="."><plain>Further analysis reveals that a polymorphism in the HB-1 gene generates a single amino acid exchange from His to Tyr at position 8 within this <z:chebi fb="7" ids="16670">peptide</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>This amino acid substitution is critical for recognition by HB-1-specific CTLs </plain></SENT>
<SENT sid="8" pm="."><plain>The restricted expression of the polymorphic HB-1 Ag by <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> cells and the ability to generate HB-1-specific CTLs in vitro using <z:chebi fb="7" ids="16670">peptide</z:chebi>-loaded dendritic cells offer novel opportunities to specifically target the immune system against <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> without the risk of evoking GVHD </plain></SENT>
</text></document>